Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran versus apixaban for heavy menstrual bleeding in menstruating patients treated for venous thromboembolism
ACTRN12625001340426Phase 4Not yet recruiting
- Sponsor
- Te Whatu Ora
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabigatran and apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Te Whatu Ora. Primary endpoints: Prevalence of heavy menstrual bleeding and Severity of heavy menstrual bleeding. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dabigatranapixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ACTRN12625001340426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001340426.